KALA BIO Stock Scheduled to Reverse Split on Monday, May 11th (NASDAQ:KALA)

Key Points

• 1-for-50 reverse split is scheduled before the market opens on Monday, May 11, with shareholders' share counts to be adjusted after the close on Friday, May 8.
• KALA BIO was trading around $0.08 (market cap ≈ $77.24M) and has a 52‑week range of $0.08–$20.60, indicating extreme volatility and a steep decline from prior highs.

KALA BIO, Inc. (NASDAQ:KALA - Free Report)'s stock is scheduled to reverse split before the market opens on Monday, May 11th. The 1-50 reverse split was announced on Thursday, May 7th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, May 8th.

KALA BIO Price Performance

Shares of NASDAQ:KALA traded down $0.03 during mid-day trading on Thursday, reaching $0.08. 8,127,962 shares of the company traded hands, compared to its average volume of 6,040,966. The company's 50 day moving average price is $0.23 and its 200-day moving average price is $0.51. The firm has a market cap of $77.24 million, a PE ratio of -0.02 and a beta of -2.23. KALA BIO has a 52 week low of $0.08 and a 52 week high of $20.60.

KALA BIO (NASDAQ:KALA - Get Free Report) last released its earnings results on Wednesday, April 15th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $1.03.

Analyst Ratings Changes

Separately, Weiss Ratings restated a "sell (e+)" rating on shares of KALA BIO in a research note on Friday, March 27th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $20.38.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in shares of KALA BIO during the fourth quarter valued at approximately $48,000. XTX Topco Ltd bought a new stake in shares of KALA BIO in the second quarter worth about $62,000. Jane Street Group LLC purchased a new stake in shares of KALA BIO in the fourth quarter worth about $80,000. Geode Capital Management LLC increased its stake in KALA BIO by 2.8% in the 2nd quarter. Geode Capital Management LLC now owns 56,367 shares of the company's stock worth $268,000 after acquiring an additional 1,534 shares during the last quarter. Finally, Baker BROS. Advisors LP grew its holdings in shares of KALA BIO by 83.1% in the fourth quarter. Baker BROS. Advisors LP now owns 1,804,055 shares of the company's stock valued at $1,003,000 after purchasing an additional 818,962 shares in the last quarter. 24.61% of the stock is currently owned by institutional investors.

KALA BIO Company Profile

KALA Bio NASDAQ: KALA is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company's proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.

Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.